Psilocybin FDA Approval for Depression: Where Things Stand

Psilocybin & Depression

134 trials

As of a 2024 analysis, 134 psilocybin clinical trials had been registered across 54 medical conditions, with zero marketing approvals anywhere in the world. COMPASS now has two Phase 3 results and plans an NDA for Q4 2026. The gap may finally be closing.

Norring & Spigarelli, Drug Design, Development and Therapy, 2024

0

psilocybin approvals globally at time of 2024 analysis

Q4 2026

COMPASS target for FDA New Drug Application

2023

year Australia first approved psilocybin for TRD

Norring & Spigarelli, Drug Design, Development and Therapy, 2024

View as image ↗

As of 2026, psilocybin FDA approval for depression is closer to reality than at any point in the drug's history. In June 2025 and again in February 2026, COMPASS Pathways announced positive results from two Phase 3 trials testing psilocybin for treatment-resistant depression. The company plans to file a New Drug Application with the FDA in the fourth quarter of 2026. A regulatory approval decision, if the application is accepted for review, could follow in late 2026 or into 2027.

That would make psilocybin the first genuinely new antidepressant mechanism to reach the US market in decades. It would also make the United States the second country in the world to formally approve psilocybin as medicine: Australia's Therapeutic Goods Administration got there first, in February 2023.

There is a complication. On February 4, 2026, the Trump administration blocked an FDA plan to fast-track the psilocybin review process, inserting political uncertainty into a timeline that had otherwise been advancing on clinical evidence. The drug still holds FDA Breakthrough Therapy Designation from three separate programs. The Phase 3 data still exists. But the path to psilocybin FDA approval for depression now involves political variables that the clinical evidence alone cannot resolve.

This article covers the peer-reviewed evidence that underpins the NDA, the Phase 3 results that have been announced but not yet published, the independent trial evidence from outside the COMPASS and Usona programs, and the realistic timeline for what comes next. For a broader look at the clinical evidence for psilocybin in depression generally, see Psilocybin for Major Depression: The Clinical Evidence.

134 Trials, 0 Approvals: Why This Gap Still Exists

Norring and Spigarelli surveyed every psilocybin trial registered on ClinicalTrials.gov at the time of their 2024 analysis and found 134 registered clinical trials across 54 potential indications, with zero marketing approvals anywhere in the world.^[3]

The headline is striking, but the explanation is structural rather than evidentiary. Psilocybin is a Schedule I controlled substance under US federal law, a classification that defines drugs as having no accepted medical use and high potential for abuse. That classification predates any modern clinical trial data on psilocybin. Changing it requires simultaneous coordination between the FDA, which evaluates medical evidence, and the DEA, which administers the scheduling system. An FDA approval and a DEA rescheduling must effectively happen together.

This is a procedural problem the US regulatory system was not designed to handle for a controlled psychedelic. The result, as Norring and Spigarelli describe it, is that the regulatory bottleneck is not the quality of the evidence. It is the infrastructure: a scheduling framework that predates psychedelic medicine, an FDA that has never approved a controlled psychedelic as a prescription product, and in 2026, a political environment that has added uncertainty to an already complicated process.

Understanding the scheduling problem is essential context for the FDA timeline. For the full history of how Schedule I status shaped psilocybin research, see Psilocybin and Schedule I: The Legal History and Path to Rescheduling.

The Phase 2 Evidence Foundation That Built the NDA Case

Before COMPASS Pathways filed anything with the FDA, the peer-reviewed evidence for psilocybin in depression accumulated across a series of randomized controlled trials that are now publicly available and independently verifiable.

Goodwin and colleagues published the pivotal Phase IIb data in the New England Journal of Medicine in 2022: the COMP360 trial enrolled 233 adults with treatment-resistant depression across 22 sites.^[1] Participants received 25mg psilocybin, 10mg psilocybin, or a 1mg control dose. At 3 weeks, the 25mg group showed a MADRS score reduction (measured on the Montgomery-Åsberg Depression Rating Scale, the standard 10-item clinician-rated scale for depression severity) 7.9 points greater than the 1mg control group, compared to 3.1 points for the 10mg group. Response rates were 29.1% for 25mg versus 9.1% for the control. This was the largest randomized controlled psilocybin trial published at the time, and it launched the Phase 3 program.

The Usona Institute ran a parallel program for a broader population. Raison and colleagues published results in JAMA in 2023: a randomized trial of a single 25mg psilocybin dose in 104 adults with major depressive disorder, not limited to treatment-resistant cases.^[2] Remission rates were 36.7% for psilocybin versus 22% for placebo at 8 weeks. The Usona design used minimal psychotherapy support, a deliberate choice to test psilocybin in conditions closer to how it might be delivered at scale. This distinguishes it from COMPASS, which built an intensive structured therapy protocol into every session.

Across both programs and multiple earlier trials, a 2025 network meta-analysis by Swieczkowski and colleagues synthesized 10 randomized placebo-controlled trials involving 1,022 participants.^[11] It confirmed a dose-response relationship: 25mg produced the largest standardized effect size and was statistically superior to 10mg and placebo. And a 2024 meta-analysis in the BMJ by Metaxa and Clarke, covering 7 RCTs, found a standardized mean difference of -0.82 in depression symptom reduction, a large effect by conventional standards.^[4]

This is the peer-reviewed evidence base that COMPASS and Usona are taking to the FDA. The effect sizes are real. The consistency across multiple study designs is the evidence base's main strength.

COMP005 and COMP006: Phase 3 Results That Are Announced, Not Published

COMPASS Pathways has completed two Phase 3 trials. Their results mark the most advanced clinical evidence for any psilocybin program, and as of April 2026, neither has been published in a peer-reviewed journal.

COMP005 was a randomized, double-blind, placebo-controlled trial enrolling 258 participants with treatment-resistant depression across 32 sites. COMPASS announced the primary endpoint result in June 2025: participants receiving a single 25mg psilocybin dose showed a MADRS reduction 3.6 points greater than placebo at 3 weeks (p less than 0.001). This result comes from a company press release. It has not been through peer review or submitted for independent verification.

COMP006, announced February 17, 2026, enrolled 568 participants and tested two doses of 25mg psilocybin given 3 weeks apart against a 1mg control condition. The reported MADRS difference was 3.8 points versus the control group (p less than 0.001); 39% of the psilocybin group achieved a reduction of 25% or more on the MADRS.

These results cross the statistical significance threshold, but the MADRS differences in Phase 3 (3.6 and 3.8 points) are smaller than those seen in the Phase IIb trial (Goodwin 2022: 7.9 points at the same dose against the same 1mg control). Whether this reflects real-world population variability, scale-up effects, or something else in the study design is a question that peer review and FDA analysis will need to address. The fact that two independent Phase 3 trials reached statistical significance in the same direction is the main regulatory takeaway.

Beyond the efficacy data, a key component of COMPASS's NDA package is the standardized therapy protocol that supports every psilocybin session. Kirlić and colleagues published this protocol in the American Journal of Psychiatry in 2025: three preparation sessions before the psilocybin dose, acute monitoring throughout the session, and integration sessions afterward.^[9] Standardizing this model across the COMP360 Phase 3 trials is central to COMPASS's regulatory submission.

Goodwin and colleagues also published long-term observational follow-up data from Phase IIb responders in 2025 in the Journal of Clinical Psychiatry: among 175 participants who were tracked post-trial, response persisted in a meaningful proportion at 3 months.^[10] This durability data directly addresses the FDA's practical question of whether the antidepressant effect requires repeated dosing.

For a detailed comparison of the COMPASS and Usona program architectures, see COMP360 vs. Usona: Comparing the Two FDA Track Psilocybin Programs.

EPISODE 2026: The Independent Confirmation the Field Needed

Alongside the COMPASS and Usona programs, a separate Phase 3-equivalent trial was published in JAMA Psychiatry in March 2026, providing evidence from completely outside the commercial development pipeline.

Mertens and colleagues published the EPISODE trial results on March 18, 2026: a randomized clinical trial of 144 adults with treatment-resistant major depression conducted across multiple German sites.^[13] This trial had no industry sponsorship from COMPASS or Usona. It was the most recently published peer-reviewed RCT of psilocybin for depression as of April 2026, and most US-focused coverage missed it entirely.

Independent replication matters in a regulatory context for a specific reason: the FDA's concern with company-sponsored trials is not misconduct, but optimization. Companies design trials to demonstrate their product's benefit. An independent research team with no stake in the outcome designing a Phase 3-equivalent trial that reaches the same directional conclusion provides evidence of a different quality.

Aaronson and colleagues added a further data point in November 2025, publishing an open-label trial in the American Journal of Psychiatry of 25 patients with severe treatment-resistant depression, defined as failing at least six prior treatments.^[7] The response rate was 60% and the remission rate was 53% at 3 weeks. Because there was no control group, the numbers cannot be used to establish efficacy in isolation. But the result in the most severely ill patient population strengthens the signal from the controlled trials.

The Safety Evidence: What the FDA Is Evaluating on Risk

The FDA weighs benefit against risk. For psilocybin, the safety data accumulated across trials over two decades is one of the field's strongest assets.

Lancelot and colleagues conducted a meta-analysis of acute adverse events across clinical trials in the Journal of Psychopharmacology in 2024.^[6] The most common adverse events were headache, nausea, anxiety, and transient increases in blood pressure. Most were mild to moderate in severity and resolved within 24 hours of the session. Serious adverse events were rare. Cardiovascular events were not significantly elevated compared to placebo across the pooled trial data.

Gukasyan and colleagues published a comprehensive safety systematic review of all published psilocybin-assisted psychotherapy trials in 2025.^[8] Serious adverse events occurred in fewer than 5% of cases across the pooled data. No cases of persistent psychosis were documented in screened populations. The conclusion was consistent: the acute safety profile of psilocybin, in screened patients with appropriate clinical support, is manageable within standard protocols.

The screened patient qualifier is important and the FDA will want to address it in labeling. Both safety reviews reflect populations from which people with personal or family history of psychotic disorders were excluded. The safety data does not characterize risk in unscreened populations. How the FDA structures the contraindication language and the prescriber certification requirements will determine how psilocybin's real-world safety profile compares to its clinical trial profile.

Australia Already Approved It: The Global Comparison

Australia's Therapeutic Goods Administration granted psilocybin formal approval for treatment-resistant depression in February 2023, making it the first country in the world to do so. Dutton and colleagues reported in the Australian and New Zealand Journal of Psychiatry in 2026 on what the first year of clinical use looked like in practice.^[12]

The Australian experience reveals what regulatory approval requires beyond the clinical data. In the first year, Australian psychiatrists and clinics encountered significant implementation challenges in every area that clinical trials do not test: training requirements for authorized practitioners, informed consent infrastructure, standardized session monitoring protocols, facility requirements, and the absence of any established reimbursement structure. The practical complexity of delivering psilocybin-assisted therapy at scale proved substantially larger than the theoretical framework had anticipated.

For the US, Australia provides two things simultaneously: proof that formal regulatory approval of psilocybin as medicine is achievable, and a practical preview of what comes after approval. A US approval would require not just FDA clearance but parallel DEA rescheduling, prescriber certification programs that do not yet exist, and clinic infrastructure that is currently found only in research settings.

A 2024 meta-analysis in Lancet Psychiatry by Ostuzzi and colleagues provides the broadest evidentiary frame: analyzing psychedelic therapies across multiple mental health conditions, the review found significant improvements in depression, anxiety, and PTSD, with psilocybin showing the largest effect on depression specifically, alongside good tolerability.^[5] It is the strength of this cross-condition evidence base that supports three active FDA Breakthrough Therapy Designations simultaneously.

The Realistic Timeline: NDA, Politics, and What Has to Happen

As of April 2026, the realistic US timeline for psilocybin approval looks like this.

COMPASS plans to submit its New Drug Application in Q4 2026. If the FDA accepts the application for substantive review (not guaranteed), a standard 10-to-12-month review period would produce a decision in late 2026 or through the first half of 2027. A priority review, which Breakthrough Therapy Designation can support, would shorten that timeline.

The Trump administration's February 4, 2026 action blocked a specific FDA mechanism for expedited review. It did not revoke the Breakthrough Therapy Designations for COMPASS, Usona, or Cybin. It did not halt existing clinical trials. What it did was introduce political uncertainty into a regulatory process that had previously been operating on standard pharmaceutical development logic. The practical effect on the NDA review timeline depends on subsequent decisions that have not yet been made.

The Usona Institute is at least two to three years behind COMPASS. Its Phase 3 uAspire trial (PSIL301) launched in March 2024, enrolling approximately 240 participants in a three-arm design (5mg versus 25mg versus placebo) for major depressive disorder rather than treatment-resistant depression. Results are not expected until 2026 at the earliest, with an NDA following.

A third program is moving on a different molecule. Cybin's CYB003 is a deuterated analog of psilocybin, chemically modified to alter its pharmacological profile. It received FDA Breakthrough Therapy Designation for MDD adjunctive treatment in October 2024. Phase 2 data showed 75% remission at 4 months at 16mg. The Phase 3 PARADIGM program is expected in the second half of 2026.

The gap between clinical evidence and approval has never been primarily about whether psilocybin has antidepressant effects. The peer-reviewed data across 10 RCTs, multiple meta-analyses, and one independent Phase 3-equivalent trial published in JAMA Psychiatry is the strongest evidence base any controlled psychedelic has ever had. The gap is about scheduling law, infrastructure, and in 2026, political variables. The evidence case for psilocybin's antidepressant effects has been made. The regulatory case is what remains.

For information on how to access psilocybin legally before an FDA decision, including clinical trial enrollment and state-level access programs in Oregon and Colorado, see Legal Psilocybin Access Before FDA Approval: All Current Options. For a look at what trials are actively running, see Phase III Psilocybin Trials: What's Running Right Now and Every Active Psilocybin Clinical Trial for Depression: A 2026 Tracker.

The Bottom Line

As of mid-2026, COMPASS Pathways has two positive Phase 3 trial results (COMP005 and COMP006, both announced by press release) and plans an FDA New Drug Application for Q4 2026. The peer-reviewed evidence base includes a 2022 NEJM Phase IIb trial (n=233), a 2023 JAMA Usona trial (n=104), a 2025 network meta-analysis of 10 RCTs (n=1,022), and the independently published EPISODE trial in JAMA Psychiatry (n=144, March 2026). Safety meta-analyses find serious adverse events in fewer than 5% of screened patients. Australia approved psilocybin for TRD in 2023. The Trump administration's February 2026 FDA fast-track block added political uncertainty to a timeline that had otherwise been advancing on evidence alone.

Frequently Asked Questions

When will psilocybin be FDA approved for depression?

As of April 2026, psilocybin is not FDA-approved. COMPASS Pathways plans to submit a New Drug Application in Q4 2026 after two positive Phase 3 trials (COMP005 and COMP006, both announced by press release). If the FDA accepts the application for substantive review, a decision could follow in late 2026 or into 2027. A Trump administration action in February 2026 blocked a specific FDA fast-track mechanism, adding political uncertainty to the timeline. Usona Institute's Phase 3 program is still recruiting, placing it at least two to three years behind COMPASS.

Is psilocybin legal for depression treatment?

In the United States, psilocybin is not FDA-approved and remains a Schedule I controlled substance, meaning it has no legal medical use under federal law. It can be accessed through clinical trial enrollment. Oregon and Colorado have created state-level frameworks allowing licensed facilitated psilocybin services, though these are not FDA-regulated medical treatments. Australia is the only country where psilocybin is fully approved as a prescription medicine for treatment-resistant depression, authorized by the Therapeutic Goods Administration in 2023.

What does FDA Breakthrough Therapy Designation mean for psilocybin?

FDA Breakthrough Therapy Designation is granted to drugs intended to treat serious conditions when early clinical evidence suggests a substantial improvement over existing therapies. Three psilocybin programs currently hold it: COMPASS Pathways for treatment-resistant depression (2018), Usona Institute for major depressive disorder (2019), and Cybin CYB003 for MDD adjunctive treatment (2024). Breakthrough Designation enables more intensive FDA guidance during development and supports a priority review of the NDA. It does not guarantee approval and does not change the drug's Schedule I status or the need for DEA rescheduling alongside FDA approval.

Has psilocybin ever been approved by the FDA?

No. As of April 2026, the FDA has never approved any psilocybin medicine. Psilocybin holds Schedule I status under federal law, which must be changed by the DEA in coordination with any FDA approval. Australia's Therapeutic Goods Administration became the first regulatory authority in the world to approve psilocybin as a prescription medicine, authorizing it for treatment-resistant depression in February 2023. A 2024 survey of ClinicalTrials.gov found 134 registered psilocybin clinical trials across 54 indications with zero marketing approvals globally at the time of analysis.

Why did the FDA block psilocybin fast-track review in 2026?

On February 4, 2026, the Trump administration blocked an FDA plan to fast-track psilocybin review. This action targeted a specific expedited review mechanism rather than revoking Breakthrough Therapy Designations (which remain active for COMPASS, Usona, and Cybin) or halting clinical trials. The practical effect on COMPASS's planned Q4 2026 NDA submission is uncertain, as the NDA process itself continues. The action introduced political variables into a regulatory process that had previously been moving on clinical evidence alone.

Where is psilocybin already legal as a medicine?

Australia is the only country where psilocybin is approved as a prescription medicine. Australia's Therapeutic Goods Administration authorized it for treatment-resistant depression in February 2023. A 2026 report in the Australian and New Zealand Journal of Psychiatry on the first year of clinical use found significant implementation challenges in practitioner training, informed consent infrastructure, and facility requirements. At the state level within the US, Oregon and Colorado have created facilitated psilocybin service frameworks that are not FDA-regulated medical treatments. No other country had issued a full national regulatory approval as of April 2026.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.
10. 10. Source details for this reference are not yet available.
11. 11. Source details for this reference are not yet available.
12. 12. Source details for this reference are not yet available.
13. 13. Source details for this reference are not yet available.